HCV Policy & Advocacy
War on Drugs Is Major Driver of Global Hepatitis C Epidemic
- Details
- Category: Injection Drug Use
- Published on Thursday, 06 June 2013 00:00
- Written by Global Commission on Drug Policy
The so-called "war on drugs" plays a major role is sustaining hepatitis C epidemics worldwide, including in hard-hit Russia and Eastern Europe, according to the latest report from the Global Commission on Drug Policy. Drug prohibition drives drug users underground and blocks harm reduction efforts such as needle exchange programs. "The war on drugs is a war on common sense," said Commissioner Ruth Dreifuss.
EASL 2013: Compassionate Access to New Hepatitis C Drugs Is an 'Emergency' for European Patients
- Details
- Category: HCV Treatment
- Published on Friday, 03 May 2013 00:00
- Written by Keith Alcorn
European governments must move quickly to ensure that compassionate use arrangements are put into place to allow access to new hepatitis C drugs for people with cirrhosis, advocates and doctors said at the EASL International Liver Congress (EASL 2013) in Amsterdam last week. However, clear differences in opinion emerged between patients and doctors regarding who should make decisions about acceptable levels of risk to patients during a symposium on compassionate use organized by the European Liver Patients Association.
New Hepatitis C Helpline Offers Information and Referrals
- Details
- Category: HCV Policy & Advocacy
- Published on Tuesday, 07 February 2012 00:00
- Written by Liz Highleyman
On February 1, The Support Partnership for Hepatitis C (TSP) launched a new project to connect people living with hepatitis C to resources and services in their communities.
EASL 2013: Triple-Drug HCV Therapy Comes with High Risk of Serious Adverse Events for Cirrhotics
- Details
- Category: HCV Treatment
- Published on Tuesday, 30 April 2013 00:00
- Written by Keith Alcorn
Currently available triple therapies for hepatitis C using HCV protease inhibitors carry a high risk of serious side effects for patients in the most urgent need of treatment, and these individuals have only a moderate chance of being cured, according to findings from studies of telaprevir and boceprevir treatment in cirrhotic patients at liver centers in France and Austria reported last week at the 48th International Liver Congress in Amsterdam. In the Austrian study almost 1 in 10 cirrhotic patients were hospitalized with sepsis during triple therapy.
AASLD and Trust for America's Health Call for Action on Hepatitis B and C
- Details
- Category: HBV Policy & Advocacy
- Published on Tuesday, 05 October 2010 13:42
- Written by Trust for America's Health
Millions of Americans are living with chronic hepatitis B or C, but many do not know they are infected and are not receiving appropriate care, according to a new report issued by the American Association for the Study of Liver Diseases (AASLD) and the Trust for America's Health (TFAH). Over years or decades, chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection can cause advanced liver disease -- including liver cirrhosis and hepatocellular carcinoma -- which is projected to be a growing public health concern in the coming years.
Web Design and Development by